Caris Life Sciences
Caris Life Sciences, a leading innovator in the field of precision medicine, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2008, the company has established itself as a key player in the biotechnology industry, focusing on molecular profiling and advanced diagnostics to enhance cancer treatment. Caris Life Sciences offers a range of unique services, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor therapies to individual patients. The company’s commitment to advancing personalised medicine has garnered recognition, positioning it as a trusted partner in oncology. With a robust portfolio of cutting-edge technologies, Caris Life Sciences continues to drive significant advancements in patient care and treatment outcomes.
DitchCarbon Score
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Caris Life Sciences's score of 22 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Caris Life Sciences's reported carbon emissions
In 2023, Caris Life Sciences reported total carbon emissions of approximately 1,463,000,000 kg CO2e from Scope 1 and 2, alongside about 4,594,000,000 kg CO2e from Scope 3 emissions. This represents a decrease from 2022, where emissions were approximately 1,760,000,000 kg CO2e for Scope 1 and 2, and about 6,680,000,000 kg CO2e for Scope 3. Despite these figures, Caris Life Sciences has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies suggests a need for further development in their sustainability efforts. The emissions data is not cascaded from any parent organisation, indicating that these figures are solely attributed to Caris Life Sciences. Overall, while the company has made strides in reducing its emissions year-on-year, the lack of formal climate pledges or targets highlights an area for potential growth in their environmental strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 6,680,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Caris Life Sciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
